The Melrose Ventures Group Issues Early Warning Report
Founders & Operators make required disclosure of its “Toehold” under the Early Warning Requirements in its Takeover of Hank Payments Corp. NAPLES, FL / ACCESSWIRE / November 6, 2024 /…
Founders & Operators make required disclosure of its “Toehold” under the Early Warning Requirements in its Takeover of Hank Payments Corp. NAPLES, FL / ACCESSWIRE / November 6, 2024 /…
SINGAPORE – Media OutReach Newswire – 6 November 2024 – Artistic Biomedical Limited Company took home two awards at this year’s Asia Pacific Enterprise Awards (APEA) 2024 Taiwan Chapter, held…
SINGAPORE – Media OutReach Newswire – 6 November 2024 – Leading education & training brand, Awesome Group, received two awards at the recent Asia Pacific Enterprise Awards (APEA) 2024 Taiwan.…
SHANGHAI, CHINA – Media OutReach Newswire – 6 November 2024 – The Asia Responsible Enterprise Awards (AREA) 2024 China Chapter recognized companies leading the way in sustainable business practices. These…
HONG KONG SAR – Media OutReach Newswire – 6 November 2024 – At the “2024 Hong Kong International ESG Awards Ceremony” held today at the Island Shangri-La Hotel, China Wantian…
Neurodiversity and Inclusion Was the Theme for PiPER UHN’s 2024 Research Day TORONTO, ON / ACCESSWIRE / November 5, 2024 / Autism Community Ventures (“ACV”), a public benefit corporation with…
KUALA LUMPUR, MALAYSIA – Media OutReach Newswire – 6 November 2024 – On the 28th of December 2024, JustMarkets hosts its Gala Dinner — the most anticipated and gorgeous event…
SOUTHLAKE, TX / ACCESSWIRE / November 5, 2024 / Transition Capital Partners (“TCP”) is pleased to announce the acquisition of Port Arthur Texas Tank (“PAT Tank”), a provider of repair,…
Drew Bambrick is set to bring the company to new heights. PRINCETON, NJ / ACCESSWIRE / November 5, 2024 / Assist America, Inc. announced today the appointment of Drew Bambrick…
NEWARK, CA / ACCESSWIRE / November 5, 2024 / Protagonist Therapeutics, Inc. (“Protagonist” or the “Company”) announced that final data from the Phase 2 REVIVE study with rusfertide in polycythemia…